Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Oncology
Chronic Myelogenous Leukemia Treatment in Turkey
Chronic myelogenous leukaemia is a slow-growing cancer of the bone marrow and blood that leads to an overproduction of white blood cells. It primarily affects older adults, though it can occur at any age, often causing fatigue, unexplained weight loss, night sweats, or abdominal fullness. Feasible disease management and therapeutic options depend on a precise specialist assessment. Compare hospitals in Turkey that treat Chronic Myelogenous Leukemia and get a free review of your medical records.
- Price from
- Price on request
- Clinics
- 2
Verified surgeons for Chronic Myelogenous Leukemia
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
About Chronic Myelogenous Leukemia
Chronic myelogenous leukaemia is a slow-growing cancer of the bone marrow and blood that leads to an overproduction of white blood cells. It primarily affects older adults, though it can occur at any age, often causing fatigue, unexplained weight loss, night sweats, or abdominal fullness. Feasible disease management and therapeutic options depend on a precise specialist assessment.
Specialty: Oncology
Best Clinics for Chronic Myelogenous Leukemia Treatment in Turkey
Frequently asked questions
The cost of treating Chronic Myelogenous Leukemia depends on the diagnosis and the treatment chosen. Doctors first review your medical records — free of charge — and you then receive an itemised quote.
Chronic Myelogenous Leukemia is treated by Oncology specialists. 2 clinics in Turkey on our platform offer this treatment.
What is Chronic Myelogenous Leukaemia and Typical Symptoms
Chronic myelogenous leukaemia (CML) is a haematological cancer arising from the marrow's blood-forming stem cells. It causes the unregulated proliferation of mature and maturing granulocytes. The condition is defined by the Philadelphia chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22, designated t(9;22). This genetic event creates the BCR-ABL1 fusion oncogene, which encodes an abnormal tyrosine kinase enzyme that drives continuous cell division.
CML progresses through three distinct phases: chronic, accelerated, and blast phase. Most individuals are diagnosed in the chronic phase, when the disease remains responsive to oral targeted therapies. Left unmanaged, it advances into accelerated or acute blast crises characterised by rapid marrow failure and elevated blast counts.
Early symptoms can be subtle or absent, with many cases identified during routine blood checks. When symptomatic, patients commonly report:
- Fatigue, generalised weakness, and exercise intolerance stemming from anaemia.
- Unexplained weight loss, heavy night sweats, and low-grade fevers.
- Left upper abdominal fullness or early satiety caused by an enlarged spleen (splenomegaly).
- Easy bruising or mucosal bleeding from platelet abnormalities.
- Bone pain or joint ache due to marrow hypercellularity.
How Chronic Myelogenous Leukaemia is Diagnosed
Accurate diagnosis requires comprehensive laboratory and genetic testing. Hospitals in Turkey conduct structured diagnostic evaluations through specialised oncology and haematology departments to guide management.
Standard investigations include:
- Full Blood Count and Smear: Quantifies elevated white cells, platelet changes, and circulating immature myeloid precursors.
- Bone Marrow Aspiration and Biopsy: Assesses overall cellularity, blast percentage, and fibrosis.
- Cytogenetics (Karyotyping): Confirms the presence of the Philadelphia chromosome and detects secondary chromosomal alterations.
- Quantitative RT-qPCR: Measures baseline BCR-ABL1 transcript levels against the International Scale to gauge future treatment depth.
- Abdominal Ultrasound: Accurately measures spleen size.
Patients travelling for medical care must bring prior records: past blood counts, bone marrow biopsy slides or tissue blocks for review, molecular PCR reports, and a list of all current medications.
Treatment Options and When Each is Used
Targeted oral therapies form the cornerstone of modern CML management. Treatment choices depend on the disease phase, mutational profile, and patient comorbidities, and must be decided by the treating haematologist after reviewing laboratory findings.
| Option | Typically used when | Things to know |
|---|---|---|
| First-Line Tyrosine Kinase Inhibitors (TKIs) | First choice for newly diagnosed chronic-phase CML. | Daily oral tablets; requires regular molecular monitoring (RT-qPCR) to track response. |
| Second- and Third-Line TKIs | Drug intolerance or resistance mutations (such as T315I). | Selected based on mutational analysis and cardiovascular risk profiles. |
| Allogeneic Stem Cell Transplant | Accelerated or blast phase, or resistance to multiple TKIs. | Curative intent with substantial risks; coordinated via specialised cellular therapies units. |
| Supportive and Cytoreductive Care | Initial diagnosis with severely elevated white cell counts. | Short-term agents like hydroxyurea combined with supportive hydration prevent metabolic complications. |
Most patients achieve prolonged disease control on oral TKIs alone without needing cytotoxic chemotherapy. Therapy requires continuous adherence and periodic monitoring.
Planning Your Treatment in Turkey
Arranging care in Turkey begins with pre-travel record review. International patient teams coordinate with haematologists to evaluate blood tests, marrow histology, and PCR reports beforehand, ensuring planned diagnostics are clear before arrival.
For diagnostic evaluations, second opinions, and initial treatment planning, a stay of 7 to 10 days is typical. This allows sufficient time for repeat blood work, bone marrow aspiration if required, molecular testing, and specialist consultation. If a new TKI regimen is started, remaining for an additional week helps the clinical team monitor tolerance and early blood counts before travel home. Stem cell transplantation requires a dedicated stay of several months.
Ongoing care at home is essential, as CML demands lifelong monitoring. You must have a local haematologist who will supervise regular blood counts and quarterly molecular PCR tests. Turkish specialists provide comprehensive English documentation and molecular baselines to facilitate ongoing shared care.
When Travel is Not Advisable and Urgent Warning Signs
Air travel or long journeys are contraindicated when acute complications arise. You should postpone overseas travel and seek urgent local medical attention if you experience:
- Transition into blast crisis, marked by rapid clinical deterioration and high peripheral blast counts.
- Severe cytopenias, including profound anaemia causing breathlessness at rest, or critically low platelets with active bleeding.
- Symptoms of leukostasis from extreme white cell counts, such as confusion, headaches, or blurred vision.
- Uncontrolled systemic infections or fevers exceeding 38°C.
- Acute, severe left upper quadrant pain suggesting splenic infarction.
In such situations, immediate local hospital stabilisation is critical before any international travel can be safely contemplated.
Frequently asked questions
Yes, the vast majority of patients with chronic-phase chronic myelogenous leukaemia receive outpatient care. Because primary treatment involves oral targeted tablets called tyrosine kinase inhibitors, prolonged hospital stays are rarely necessary unless complications arise. When travelling abroad for consultation, you typically visit the clinic for blood tests, bone marrow evaluation, and prescription planning, remaining in a nearby hotel between appointments.
The BCR-ABL1 test uses quantitative polymerase chain reaction (RT-qPCR) to measure leukaemia cells at a genetic level. It is the gold standard for monitoring treatment success. Haematologists evaluate your response at three, six, and twelve months to verify whether transcript levels are dropping appropriately. Achieving deep molecular milestones indicates that targeted therapy is working effectively and helps guide long-term management decisions.
Most patients take tyrosine kinase inhibitors indefinitely to keep the disease suppressed. In carefully selected individuals who have maintained deep, stable molecular remission for several consecutive years, haematologists may discuss a closely monitored treatment-free remission trial. However, this is only attempted under strict medical supervision with frequent molecular testing, as premature discontinuation can allow leukaemia cells to multiply again.
Tyrosine kinase inhibitors can cause harm to a developing foetus, meaning conception while taking these medications is strictly contraindicated. If you wish to start a family, you must discuss family planning with your haematologist well in advance. In stable disease, doctors may explore safe temporary treatment interruptions or alternative strategies, but decisions require precise timing and rigorous molecular surveillance.
You should always maintain open communication between your home haematologist and overseas specialists. Chronic myelogenous leukaemia requires lifelong or long-term monitoring, meaning your local physician will manage regular blood draws and prescriptions. Share all overseas clinical notes, pathology slides, and molecular reports with your local provider. A coordinated, collaborative approach ensures your treatment remains safe, consistent, and well aligned with international clinical guidelines.